Phase 1 N=32 A First Human Study of a Ferroportin Antibody
Healthy Volunteers
Primary: Number of Participants With Clinically Significant Adverse Effects — 7; 6; 5; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD). — 0; 0; 3; 2 participants
Phase 1 N=43 A Study of LY3084077 in Healthy Participants
Healthy Volunteers
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 1; 0; 0; 0 participants
Phase 1 N=12 Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known
Leukemia · Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants
Phase 1 N=63 A Study of LY3050258 in Healthy Participants
Healthy Volunteers
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 1 N=28 Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Overview of Treatment-emergent Adverse Events (TEAEs) — 3; 13; 11; 2 Participants
Phase 1 N=66 A Study of Multiple Doses of LY2922470 in Participants With Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 1 N=49 A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia
Hypercholesterolemia · Dyslipidemias · Hyperlipidemias
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-04950615 — 65810; 15900; 8922; 10470 nanogram per milliliter (ng/mL)
Phase 1 N=13 [18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
Alzheimer's Disease · Amnestic Mild Cognitive Impairment
Primary: Number of Participants With Adverse Events (AEs) — 1; 3; 2 Participants
Phase 1 N=120 A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.
Respiratory Disorders
Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs) — 2; 19; 26; 6 Participants
Phase 1 N=36 A Study of LY3050258 in Healthy Participants
Healthy Participants
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 1 N=41 A Study of LY3053102 in Healthy Participants
Healthy Volunteers
Primary: Number of Participants With One or More Adverse Events (AEs) or Any Serious AEs — 5; 6; 4; 4 participants
Phase 1 N=56 A Study of LY3016859 in Healthy Volunteers
Healthy Volunteers
Primary: Number of Participants With One or More Drug-Related Treatment-Emergent Adverse Events (TEAEs) or Any Serious AEs (SAE) — 2; 0; 2; 3 participants
Phase 1 N=59 A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Phase 1 N=9 A Study of LY2584702 in Solid Tumors
Cancer
Primary: Number of Participants With Clinically Significant Effects — 0; 0 Participants